

Article

Organosilicon Compounds, SILA-409 and SILA-421, as Doxorubicin Resistance-Reversing Agents in Human Colon Cancer Cells

Olga Wesółowska ^{1,*} , Krystyna Michalak ¹ , Maria Błaszczuk ¹ , Joseph Molnár ² and Kamila Środa-Pomianek ¹ 

¹ Department of Biophysics and Neuroscience, Wrocław Medical University, 50-367 Wrocław, Poland; krystyna.michalak@umed.wroc.pl (K.M.); maria.blaszczuk@student.umed.wroc.pl (M.B.); kamila.sroda-pomianek@umed.wroc.pl (K.Ś.-P.)

² Institute of Medical Microbiology and Immunobiology, University of Szeged, 6720 Szeged, Hungary; molnar.jozsef@med.u-szeged.hu

* Correspondence: olga.wesolowska@umed.wroc.pl; Tel.: +48-71-784-14-15

Received: 18 March 2020; Accepted: 1 April 2020; Published: 3 April 2020



Abstract: Multidrug resistance (MDR) that occurs in cancer cells constitutes one of the major reasons for chemotherapy failure. The main molecular mechanism of MDR is overexpression of protein transporters from the ATP-binding cassette (ABC) superfamily, such as ABCB1 (multidrug resistance protein 1 (MDR1), P-glycoprotein). At the expense of ATP hydrolysis, ABCB1 pumps a diverse range of substrates (including anticancer drugs) out of the cell, thereby reducing their intracellular concentration. In the present study, the ability of two patented disiloxanes (SILA-409 and SILA-421) to reverse drug resistance in human colon adenocarcinoma cell lines LoVo and LoVo/Dx was investigated. It was demonstrated that both compounds in concentrations of 0.5–1 μ M strongly increased the sensitivity of LoVo/Dx cells to doxorubicin. By means of an accumulation test in which rhodamine 123 was used as an ABCB1 substrate analogue, both organosilicon compounds were also shown to inhibit ABCB1 transport activity. The intracellular accumulation of doxorubicin was also increased, and more drug entered the cellular nuclei of resistant cells in the presence of the studied compounds. In conclusion, both SILA-409 and SILA-421 were demonstrated to be effective MDR reversal agents in resistant human colon cancer cells.

Keywords: organosilicon compounds; SILA-409 (Alis-409); SILA-421 (Alis-421); multidrug resistance (MDR) reversal; ABCB1 (P-glycoprotein); colon cancer

1. Introduction

Since chemotherapy continues to be a method of choice for the treatment of various types of cancer, any factors that undermine its effectiveness constitute a serious therapeutic issue. In the majority of patients, the initial response to chemotherapy is satisfactory; however, the occurrence of multidrug resistance (MDR) during treatment results in a development of progressive disease [1,2]. Cells displaying the MDR phenotype are no longer vulnerable to cytotoxic actions of many functionally and structurally dissimilar anti-cancer drugs.

Among several mechanisms that may lead to the development of MDR, the overexpression of ATP-binding cassette (ABC) transporters such as ABCB1 (P-glycoprotein, MDR1: multidrug resistance protein 1), ABCC1 (MRP1: multidrug resistance-associated protein 1), and ABCG2 (BCRP: breast cancer resistance protein) proteins seems to prevail [3,4]. It was recently reported that non-ABC transporters such as Hedgehog receptor Patched were also engaged in doxorubicin (Dox) efflux and conferred Dox resistance to cancer cells [5,6]. ABCB1 is a transporter that utilizes the energy gained

from the hydrolysis of ATP to pump many structurally variable substrates (including xenobiotics and chemotherapeutics) out of the cell [7]. Among the numerous strategies proposed to overcome MDR, the most basic approach is the idea to use the inhibitor of a multidrug transporter (MDR modulator) along with chemotherapy in hopes to increase the intracellular accumulation of an anti-cancer drug and to improve the outcome of the treatment. Although this approach is yet to result in any clinical success [8–10], the search for new substances that could serve as clinically applicable MDR modulators is continuously ongoing.

Silicon is a metalloid, which is a group of chemical elements also called semi-metals [11]. It can form chemical bonds with carbon and oxygen, and silicon-containing compounds are widely used in medicine and engineering. Silicone is a synthetic polymer composed of repeating siloxane units. Due to its high biocompatibility and favorable mechanical properties, silicone is used for the production of various medical implants (e.g., breast or testicle), as well as contact lenses [11]. On the other hand, silica materials are applied as controlled drug delivery systems and three-dimensional scaffolds for tissue engineering [11]. The introduction of a silicon atom to a structure usually yields a molecule of higher lipophilicity than its carbon analogue. The increased anti-cancer activity of silicon–indomethacin derivatives was recorded, and it was claimed that the higher lipophilicity of silicon derivatives resulted in their increased uptake by cancer cells [12]. New sila-organosulfur compounds were recently synthesized that were reported to be effective anti-cancer and antibacterial agents [13].

SILA-409 and SILA-421 are water-soluble disiloxanes that were synthesized and patented as putative MDR modulators [14]. They were previously demonstrated to increase fluorescent dye accumulation in human *ABCB1* gene-transfected mouse lymphoma cells and, to much lesser extent, in colon carcinoma Colo320/MDR1-LRP cells, but not in ABCC1 expressing breast cancer (HTB-26/MRP1) and stomach cancer (257P/MDR) cells, which was attributed to their specific interactions with the *ABCB1* transporter [15]. The specificity of disiloxanes toward *ABCB1* was corroborated in a study by Kars et al. conducted in a model system of breast cancer cells [16]. Recently, the synergism between disiloxanes and amyloid β -protein in the inhibition of *ABCB1* transporter activity was reported [17]. In an in vivo study on mice bearing human pancreatic cancer xenografts, the application of SILA-409 resulted in the reduction of tumor growth that was accompanied by increased apoptosis and a reduced level of *ABCB1* protein in cancer cells [18]. SILA-421 was found to cause cell-cycle arrest and apoptosis in several non-MDR cancer cell lines [19]. The analysis of the global gene expression profile of HL-60 leukemia cells treated with this compound revealed multiple cellular pathways affected by SILA-421, including DNA replication and transcription processes. Interference with these processes was also attributed to the antimicrobial activity of SILA-409 and SILA-421 compounds [20–22], as well as their ability to eliminate resistance-bearing plasmids from *Escherichia coli* strains [23]. Additionally, the weak chemopreventive activity of disiloxanes was reported both in vitro and in vivo [24].

In the present work, the ability of SILA-409 and SILA-421 to reverse Dox resistance in human adenocarcinoma cells LoVo/Dx was demonstrated. The disiloxanes inhibited the transport function of *ABCB1* protein both in LoVo/Dx cells and in Madin-Darby Canine Kidney (MDCK) cells expressing human *ABCB1* (MDCK-MDR1). The amount of Dox accumulated inside LoVo/Dx cells was also elevated in the presence of studied compounds, and its distribution pattern was changed.

2. Results and Discussion

2.1. Cytotoxicity of Disiloxanes

A human adenocarcinoma cell line sensitive to Dox (LoVo) and its Dox-resistant counterpart (LoVo/Dx) were employed as a model system. It was previously demonstrated that the increased expression of *ABCB1* transporter is mainly responsible for the resistance of LoVo/Dx cells [25]. The cytotoxicity of both SILA-409 and SILA-421 to LoVo and LoVo/Dx cells was comparable (Figure 1). Both compounds were strongly cytotoxic to the cells in concentrations above 10 μ M. The half maximal inhibitory concentration (IC_{50}) values of SILA-409 were 15.6 μ M and 24.6 μ M for LoVo and LoVo/Dx

cells, respectively. For SILA-421, IC_{50} values were 8.4 μM in LoVo cells and 9.2 μM in LoVo/Dx cells. SILA-421 was more toxic than SILA-409, which might be the result of the higher lipophilicity of this compound.




Figure 1. Cytotoxicity of SILA-409 (A) and SILA-421 (B) to LoVo (open symbols) and LoVo/Dx cells (full symbols). Means of three experiments \pm SD are presented.

The cytotoxicity of both disiloxanes to MDCK cells and MDCK transfected with human *ABCB1* gene (MDCK-MDR1) was similar (Figure S1, Supplementary Materials). Both compounds in concentrations below 5 μM slightly stimulated cell growth, whereas, in concentrations of 25 μM and higher, <10% of cells survived. IC_{50} values of SILA-409 in MDCK and MDCK-MDR1 cells were 14.2 μM and 13.9 μM , respectively. For SILA-421, the values of 11.6 μM and 12.1 μM were analogously recorded. Similarly to the findings in colon cancer cells, IC_{50} values for SILA-421 were slightly lower than those for SILA-409.

The cytotoxicity of the studied disiloxanes to various cancer cell lines reported previously [15,19] was similar to the results of the present study. The IC_{50} values of SILA-421 analyzed in several various cancer cell lines, as well as in normal cells HEK-293, lay within the range 5–35 μM [19]. In another study, the cytotoxicity of both SILA-409 and SILA-421 was assessed in a panel of multidrug resistant cancer cell lines of different patterns of expression of MDR-associated transporters [15]. IC_{50} values

varied from 8–80 μM depending on cell line. In three out of five cell lines studied, SILA-421 was found to be slightly more cytotoxic than SILA-409.

The analysis of the disiloxanes' chemical structures (Figure S3, Supplementary Materials) and the calculation of their theoretical logP values, performed using the free web tool Molinspiration (<https://www.molinspiration.com/cgi-bin/properties>), demonstrated that SILA-421 was more lipophilic than SILA-409 (logP values were 5.83 and 9.60 for SILA-409 and SILA-421, respectively). Lipophilicity was observed to positively correlate with the antiproliferative activity of various compounds toward cancer cells [26,27]. However, in other experimental settings, molecular parameters other than lipophilicity were found to affect cytotoxicity to the highest extent [28,29]. Therefore, a larger series of disiloxanes and a characterization of more of their molecular descriptors would be required to determine the effect of lipophilicity on the biological activity of these compounds.

2.2. Influence of Disiloxanes on Doxorubicin Cytotoxicity

Next, the influence of the studied modulators on Dox cytotoxicity was investigated (Figure 2). SILA-409 and SILA-421 were applied in concentrations in which they killed <10% of LoVo/Dx cells. The treatment of cells with a combination of either SILA-409 or SILA-421 with Dox significantly reduced the survival rate of resistant colon cancer cells, i.e., the disiloxanes partially reversed Dox resistance. Non-toxic concentrations of SILA-409 and SILA-421 were applied together with doxorubicin. Sensitive LoVo cells were more vulnerable to this anticancer drug (IC_{50} Dox = 4.0 μM) than ABCB1-overexpressing LoVo/Dx cells (IC_{50} Dox = 30.0 μM) [30]. It was demonstrated that both compounds strongly increased the sensitivity of LoVo/Dx cells to doxorubicin without changing the sensitivity of LoVo cells to this drug. The value of IC_{50} for Dox was reduced to 5.7 μM in the presence of SILA-409 at 0.5 μM concentration, and to 6.1 μM in the presence of SILA-421 (1 μM). The isobolographic analysis applied to the obtained results revealed the existence of synergism between Dox and each of the studied disiloxanes (Table 1).

Table 1. Combination of disiloxanes with Dox against LoVo/Dx cell growth.

Concentration (μM)		Ratio	Combination Index
Dox	SILA-409		
8.62	0.5	17.24:1	0.7772
17.24	0.5	34.48:1	0.6136
	SILA-421		
8.62	1	8.62:1	0.6467
17.24	1	17.24:1	0.5632

Dose and effect data were obtained from the sulforhodamine B (SRB) assay (mean values of three experiments) and subjected to CompuSyn analysis. CI (combination index) values were generated by CompuSyn software. CI = 1 indicates additive effect, CI < 1 indicates synergism, and CI > 1 indicates antagonism.




Figure 2. The changes in doxorubicin (Dox) cytotoxicity in LoVo (circles) and LoVo/Dx cells (squares) caused by SILA-409 at 0.5 μM (A) and SILA-421 at 1 μM (B). Open symbols represent cells treated with Dox only, whereas full symbols represent cells treated with Dox and the modulator. Means of three experiments \pm SD are presented.

The reduction of Dox cytotoxicity by SILA-409 and SILA 421 was previously observed in human *ABCB1* gene-transfected mouse lymphoma cells (L5718/MDR) and the resistant colon cancer cell line (Colo320/MDR1-LRP) [15]. Synergism between disiloxanes and Dox was observed in these cell lines but not in breast cancer cell lines MCF-7, T47-D, and HTB-26/MDR1. The authors concluded that the presence of a functional *ABCB1* transporter was essential for disiloxanes to be able to revert Dox resistance [15]. This pointed to the specific interactions between SILA-409 and SILA-421 and *ABCB1* protein. Similar synergistic interactions with appropriate anticancer drugs were also observed for SILA-409 and SILA-421 in MCF-7 cell lines resistant to paclitaxel and docetaxel, but not in the sublines resistant to Dox and vincristine [16].

Dox cytotoxicity was significantly lower ($p < 0.05$) in LoVo/Dx than in LoVo cells as determined by Student's *t*-test. Significant enhancement ($p < 0.05$) of Dox cytotoxicity was recorded for both SILA-409 and SILA-421 in LoVo/Dx cells in the whole concentration range

2.3. Intracellular Accumulation of Rhodamine 123 (R123)

Rhodamine 123 (R123) is popularly used as a fluorescent reporter substrate of the ABCB1 transporter. Both SILA-409 and SILA-421 caused an increase in R123 accumulation in LoVo/Dx and MDCK-MDR1 cells (Figure 3) in a concentration-dependent manner, which suggested that both compounds were inhibitors of ABCB1 transport activity. SILA-421 seemed to exert its inhibitory action in lower concentrations than SILA-409, which significantly elevated fluorescence intensity ratio (FIR) values only in concentrations above 10 μM in Dox-resistant colon cancer cells.




Figure 3. The influence of SILA-409 (gray) and SILA-421 (white) on R123 intracellular accumulation in LoVo/Dx (A) and Madin-Darby Canine Kidney-multidrug resistance protein 1 (MDCK-MDR1) cells (B). Means \pm SD of three experiments are presented. The statistically significant differences from the untreated cells were determined using Student's *t*-test (* $p < 0.05$).

Molnar et al. [15] also observed increased R123 accumulation in human *ABCB1* gene-transfected mouse lymphoma cells (L5718/MDR) treated with SILA-409 and SILA-421 in concentrations up to 2 $\mu\text{g}/\text{mL}$. Both compounds demonstrated similar activity in this respect. They were, however, unable to affect R123 accumulation in sensitive breast and prostate cancer cells and it was again concluded that the activity of disiloxanes can only be observed in cell lines that express a functional *ABCB1* transporter [15]. In the study of Kars et al. [16], both disiloxanes were demonstrated to increase R123 accumulation in a series of breast cancer cell lines resistant to paclitaxel, docetaxel, Dox, and vincristine. In contrast to our findings, SILA-409 was observed to be more active than SILA-421 in this experimental setting.

2.4. Intracellular Accumulation of Doxorubicin

Accumulation of Dox itself by human colon cancer cells was also investigated. As presented in Figure 4, drug-sensitive LoVo cells accumulated more drug than Dox-resistant LoVo/Dx cells. The treatment of cells by disiloxanes at a concentration of 5 μM resulted in a significant increase in Dox accumulation by LoVo/Dx cells with apparently no effect observed in LoVo cells.




Figure 4. Intracellular doxorubicin (Dox) accumulation in LoVo (gray bars) and LoVo/Dx cells (white bars) treated with SILA-409 and SILA-421 at 5 μM concentration. Means \pm SD of three experiments are presented. The statistically significant differences between untreated and disiloxane-treated cells were determined using Student's *t*-test (* $p < 0.05$).

Since Dox is characterized by strong intrinsic fluorescence, its intracellular accumulation may also be examined directly by means of fluorescence microscopy. Again, LoVo cells accumulated more Dox than LoVo/Dx cells (Figure 5 and Figure S2, Supplementary Materials), and the application of disiloxanes at a concentration of 5 μM resulted in an increase in accumulation of the drug in Dox-resistant cells but not in the sensitive ones. SILA-421 was more effective in this respect than SILA-409. The intracellular distribution of Dox was also affected by organosilicon compounds. Dox that was excluded from the nuclei of untreated resistant cells was demonstrated to localize within these organelles in modulator-treated LoVo/Dx cells.




Figure 5. Intensity of intracellular fluorescence of Dox, measured by ImageJ software, in LoVo (gray bars) and LoVo/Dx cells (white bars) treated with 5 μ M of SILA-409 and SILA-421 is presented as the mean fluorescence values \pm SD measured in 20 representative cells. The statistically significant differences from the untreated cells were determined using Student's *t*-test (* $p < 0.05$).

According to our best knowledge, the influence of SILA-409 and SILA-421 on Dox accumulation and cellular localization was not previously studied. The pattern of changes in Dox accumulation caused by disiloxanes was similar to the changes caused by verapamil (a well-known inhibitor of ABCB1 protein) observed previously in the same colon cancer cell lines as those used in the present work [25].

2.5. Expression of ABCB1 Transporter

Additionally, the influence of disiloxanes on ABCB1 transporter expression was analyzed by Western blotting (Figure 6). Both SILA-409 and SILA-421 significantly decreased ABCB1 protein level in LoVo/Dx cells during 48 h of treatment. SILA-421 turned out to be more active in this respect in comparison with SILA-409. No effect of organosilicon compounds on ABCB1 protein level was noted during 60 min of treatment with modulators (data not shown).




Figure 6. Western blot analysis of ATP-binding cassette B1 (ABCB1) protein level (A) in LoVo/Dx cells cultured with 0.5 μ M SILA-409 and SILA-421 for 48 h. The molecular masses of the proteins are indicated on the left side of the gel. β -Glucuronidase (β -GUS) was used as a reference protein. The relative level of ABCB1 expression (B) was normalized to the control derived from non-treated LoVo/Dx cells. The results of three experiments \pm SD are presented. The statistically significant differences from the untreated controls were determined using Student's *t*-test (* $p < 0.05$).

The downregulation of ABCB1 expression was previously demonstrated using immunohistochemical methods in pancreatic tumor samples isolated from mice treated with SILA-409 [18]. On the other hand, no influence of disiloxanes (tested in concentrations of 380–500 μ g/mL) on ABCB1 expression level was detected in mouse T-lymphoma cells transfected with human ABCB1 [15].

3. Materials and Methods

3.1. Chemicals

Organosilicon compounds 1,3-dimethyl-1,3-bis(4-fluorophenyl)-1,3-bis(3-morpholino-propyl)disiloxan dihydrochloride (SILA-409) and 1,3-dimethyl-1,3-bis(4-fluorophenyl)-1,3-bis[3-[1(4-butylpiperazinyl)]-propyl]-disiloxan tetrahydrochloride (SILA-421) were synthesized and patented [14]. Their chemical structures are presented in Figure S3 (Supplementary Materials). Stock solutions of organosilicon compounds were prepared in dimethyl sulfoxide (DMSO). Sulforhodamine B (SRB), rhodamine 123 (R123), and doxorubicin (Dox) were obtained from Sigma-Aldrich (Poznan, Poland) and dissolved in water.

3.2. Cell Culture

Human colorectal adenocarcinoma cell line, LoVo, and its resistant subline, LoVo/Dx, obtained by prolonged exposure to Dox [31], were obtained from the Institute of Immunology and Experimental Therapy of Polish Academy of Science (Wroclaw, Poland). Cultivation conditions were Ham's F12 medium (with the addition of 10% fetal bovine serum, L-glutamine, antibiotics, and, in the case of LoVo/Dx cells, Dox at 100 ng/mL), at 37 °C and 5% CO₂.

Madin-Darby Canine Kidney cells (MDCK) and MDCK cells expressing human ABCB1 (MDCK-MDR1) [32] were purchased from the Netherlands Cancer Institute (NKI-AVL, Amsterdam, the Netherlands). The cells were cultured in DMEM medium supplemented with 10% fetal bovine serum, L-glutamine, and antibiotics at 37 °C and 5% CO₂.

3.3. Cell Viability Assay

The SRB assay [33] with minor modifications was used for the estimation of the effect of the studied compounds on cell growth. Cells were seeded in 96-well flat-bottom microtiter plates in 75 µL of medium and allowed to attach (60 min, 37 °C). Then, 75 µL of medium containing an amount of the studied compounds (such that a desired compound concentration was obtained in a final sample volume) was added to each well, with the exception of the control wells, which contained medium only. The culture plates were then incubated for 48 h at 37 °C. The further procedure was carried out as previously described [34]. Cytotoxicity of DMSO to LoVo and LoVo/Dx cells was negligible.

3.4. Isobolographic Analysis

Combination index (CI) values were calculated using the CompuSyn software (www.combosyn.com, ComboSyn, Inc., Paramus, USA) according to the classic median-effect equation as described by Chou and Martin [35].

$$CI = \frac{(D)_1}{(Dx)_1} + \frac{(D)_2}{(Dx)_2}, \quad (1)$$

where (Dx)₁ is the dose of drug 1 alone that inhibits a system by x%, (Dx)₂ is the dose of drug 2 alone that inhibits a system by x%, and (D)₁ + (D)₂ are doses of drugs 1 and 2 in combination that also inhibit a system by x%.

3.5. Accumulation of Rhodamine 123 in Cancer Cells

In order to determine R123 accumulation, the cells were harvested and incubated (300,000 cells/mL) with the appropriate concentration of the studied compound (15 min; 25 °C). Next, R123 (10 µM) was added, and the cells were incubated for 60 min at 37 °C. After centrifugation, the samples were washed twice with ice-cold phosphate-buffered saline (PBS) and dissolved in lysis buffer (20 mM Tris-HCl, 0.2% SDS, pH = 7.7). Intracellular fluorescence (λ_{ex} = 485 nm, λ_{em} = 538 nm) was collected with the use of an Infinite M200Pro plate reader (Tecan Instruments, Maennedorf, Switzerland). Based on measured

the fluorescence intensity (FL) of the treated and control samples (without modulator), the fluorescence intensity ratio (FIR) was calculated according to the following equation:

$$\text{FIR} = \frac{(\text{FL}_{\text{LoVoDx or MDCK-MDR1 treated}}) / (\text{FL}_{\text{LoVoDx or MDCK-MDR1 control}})}{(\text{FL}_{\text{LoVo or MDCK treated}}) / (\text{FL}_{\text{LoVo or MDCK control}})}. \quad (2)$$

3.6. Intracellular Accumulation of Doxorubicin

Intracellular Dox accumulation was detected with a fluorimetry based assay as described previously [36]. Briefly, cells were seeded (800,000/well) onto a six-well plate and incubated for 24 h at 37 °C. Then, the cells were incubated in PBS containing Dox (4 µM) and treated with the modulators. After 48 h of incubation, cells were washed twice in ice-cold PBS and detached. Next, cells were centrifuged and lysed. The cellular protein content was determined using the standard method of Bradford reaction [37]. Dox content was measured using an LS-5 spectrofluorimeter (Perkin-Elmer, Beaconsfield, UK). Excitation and emission wavelengths were 475 and 553 nm, respectively. Fluorescence was expressed in ng of Dox per mg of cellular protein with the use of the calibration curve prepared previously.

For fluorescence microscopic experiments, LoVo and LoVo/Dx cells were cultivated on eight-well µ-Slide microscopy chambers (Ibidi, Munich, Germany) for 48 h. For the experiment, a fresh portion of F12 medium was added containing 50 µM Dox (plus 5 µM of the studied compounds in treated samples), and cells were incubated for 60 min at 37 °C. After incubation, the chambers were washed with PBS and with serum- and phenol red-free F12 medium. The images were collected with a Nikon Eclipse TE2000-E microscope. Fluorescence was excited in the range 528–553 nm and collected in the range 578–633 nm.

3.7. Expression of ABCB1 Protein

Cell lysates were prepared in ice-cold lysis buffer (1% Triton X-100, 50 mM Hepes, 150 mM NaCl, 1.5 mM MgCl₂, 1 mM ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), 1 mM phenylmethylsulfonyl fluoride (PMSF), 100 mM NaF, 10 mM sodium pyrophosphate, 10 µg/mL aprotinin, and 10% glycerol, pH 7.4). After centrifugation of whole-cell lysates (13,000× g, 10 min, 4 °C), the supernatants were taken for analysis. The standard method of Bradford reaction was used to measure protein content (Bradford, 1976). The proteins were subjected to SDS-PAGE, transferred to polyvinylidene difluoride (PVDF) membranes, and detected using primary antibodies in tris-buffered saline with Tween (TBS-T) buffer (0.1% Triton X-100, 50 mM Tris-HCl, 150 mM NaCl, 1, pH 7.4) with 5% bovine serum albumin (BSA). The anti-ABCB1 mouse monoclonal primary antibodies (C494) (Alexis) were used at dilution 1:1000. The level of β-glucuronidase (β-GUS) was also determined as a reference protein (anti-glucuronidase mouse monoclonal antibody, diluted 1:1000, Thermo Scientific). After incubation (overnight at 4 °C), the membranes were washed in TBS-T and incubated with rabbit anti-mouse immunoglobulin G (IgG) secondary antibody conjugated to horseradish peroxidase (HRP) (dilution 1:1000, Thermo Scientific) for 30 min at 4 °C. The membranes were then washed with TBS-T, and the proteins were visualized. The relative amount of protein normalized to the control (non-treated cells) was determined. The optical density of the bands on the electrophoregram was detected with the Image J software version 1.43m.

3.8. Statistical Analysis

Data represent the means ± standard deviation (SD) of at least three replications. Student's *t*-test was applied, and *p*-values less than 0.05 were considered to be statistically significant.

4. Conclusions

Organosilicon compounds, SILA-409 and SILA-421, were demonstrated to reverse doxorubicin resistance in a human colon cancer cell line. Both compounds were inhibitors of the transport

function of ABCB1 protein judging from the increased accumulation of R123 by modulator-treated cells. Intracellular accumulation of Dox was also increased, and more drug entered cellular nuclei in the presence of the studied compounds. SILA-421 demonstrated slightly higher activity than SILA-409. Additionally, the decreased expression of ABCB1 protein after treatment with disiloxanes was recorded. Therefore, the studied compounds acted as resistance-reversing agents via two mechanisms. They were effective inhibitors of the ABCB1 transport function, and its reduction was easily observed after 60 min of disiloxane treatment (e.g., in fluorescence microscopy and R123 accumulation experiments). Moreover, after prolonged treatment with SILA-409 and SILA-421, the reduction of ABCB1 protein level that occurred certainly increased the MDR-reversing potency of these compounds. In conclusion, both SILA-409 and SILA-421 were demonstrated to be effective anti-MDR agents in resistant human colon cancer cells.

Supplementary Materials: The following are available online at <http://www.mdpi.com/1420-3049/25/7/1654/s1>: Figure S1: Cytotoxicity of SILA-409 (A) and SILA-421 (B) to MDCK (full symbols) and MDCK-MDR1 cells (open symbols). Means of three experiments \pm SD are presented; Figure S2: Fluorescence microscopy images illustrating doxorubicin accumulation in LoVo (A) and LoVo/Dx (B) cells treated with 5 μ M SILA-409 (C and D for LoVo and LoVo/Dx, respectively) and with 5 μ M SILA-421 (E and F). Scale bar is 50 μ m. Illumination conditions were the same for all images; Figure S3: Chemical structures of SILA-409 and SILA-421.

Author Contributions: Conceptualization, O.W. and K.M.; Validation, O.W.; Formal analysis, O.W. and K.Š.-P.; Investigation, O.W., K.Š.-P., and M.B.; Resources, J.M.; Writing—Original draft preparation, O.W.; Writing—Review and editing, O.W., K.Š.-P., J.M. and K.M.; Visualization, O.W.; Supervision, K.M.; Funding acquisition, K.M. All authors have read and approved the final version of the manuscript.

Funding: This work was financed by Wrocław Medical University, subject Simple No. SUB.A050.20.018. J.M. was supported by the Szeged Foundation for Cancer Research.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Gottesman, M.M. Mechanisms of cancer drug resistance. *Ann. Rev. Med.* **2002**, *53*, 615–627. [[CrossRef](#)] [[PubMed](#)]
2. Li, W.; Zhang, H.; Assaraf, Y.G.; Zhao, K.; Xu, X.; Xie, J.; Yang, D.H.; Chen, Z.S. Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. *Drug Resist. Updat.* **2016**, *27*, 14–29. [[CrossRef](#)] [[PubMed](#)]
3. Szakacs, G.; Paterson, J.K.; Ludwig, J.A.; Booth-Genthe, C.; Gottesman, M.M. Targeting multidrug resistance in cancer. *Nat. Rev. Drug Discov.* **2006**, *5*, 219–234. [[CrossRef](#)] [[PubMed](#)]
4. Choi, Y.H.; Yu, A.M. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. *Curr. Pharm. Des.* **2014**, *20*, 793–807. [[CrossRef](#)] [[PubMed](#)]
5. Bidet, M.; Tomico, A.; Martin, P.; Guizouarn, H.; Mollat, P.; Mus-Veteau, I. The Hedgehog receptor patched functions in multidrug transport and chemotherapy resistance. *Mol. Cancer Res.* **2012**, *10*, 1496–1508. [[CrossRef](#)]
6. Hasanovic, A.; Ruggiero, C.; Jung, S.; Rapa, I.; Signetti, L.; Ben Hadj, M.; Terzolo, M.; Beuschlein, F.; Volante, M.; Hantel, C.; et al. Targeting the multidrug transporter Patched potentiates chemotherapy efficiency on adrenocortical carcinoma in vitro and in vivo. *Int. J. Cancer* **2018**, *143*, 199–211. [[CrossRef](#)]
7. Sharom, F.J. ABC multidrug transporters: Structure, function and role in chemoresistance. *Pharmacogenomics* **2008**, *9*, 105–127. [[CrossRef](#)]
8. Shukla, S.; Wu, C.P.; Ambudkar, S.V. Development of inhibitors of ATP-binding cassette drug transporters: Present status and challenges. *Expert Opin. Drug Metab. Toxicol.* **2008**, *4*, 205–223. [[CrossRef](#)]
9. Kelly, R.J.; Draper, D.; Chen, C.C.; Robey, R.W.; Figg, W.D.; Piekarczyk, R.L.; Chen, X.; Gardner, E.R.; Balis, F.M.; Venkatesan, A.M.; et al. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. *Clin. Cancer Res.* **2011**, *17*, 569–580. [[CrossRef](#)]

10. Cripe, L.D.; Uno, H.; Paietta, E.M.; Litzow, M.R.; Ketterling, R.P.; Bennett, J.M.; Rowe, J.M.; Lazarus, H.M.; Luger, S.; Tallman, M.S. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: A randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. *Blood* **2010**, *116*, 4077–4085. [[CrossRef](#)]
11. Sekhon, B.S. Metalloid compounds as drugs. *Res. Pharm. Sci.* **2013**, *8*, 145–158. [[PubMed](#)]
12. Gately, S.; West, R. Novel therapeutics with enhanced biological activity generated by the strategic introduction of silicon isosteres into known drug scaffolds. *Drug Develop. Res.* **2007**, *68*, 156–163. [[CrossRef](#)]
13. Mousazadeh, H.; Milani, M.; Zarghami, N.; Alizadeh, E.; Safa, K.D. Study of the cytotoxic and bactericidal effects of sila-substituted thioalkyne and mercapto-thione compounds based on 1,2,3-triazole scaffold. *Basic Clin. Pharmacol Toxicol.* **2017**, *121*, 390–393. [[CrossRef](#)] [[PubMed](#)]
14. Varga, A.; Hegyes, P.; Molnar, J.; Mucsi, I.; Hever, A.; Szabo, D.; Kiesig, S.; Lage, H.; Gaal, D.; Nacs, J. Substituted Disiloxanes, Method for the Production Thereof and the Use Thereof for Reversal of Multidrug Resistance (MDR). EP Patent 1 432 717 B1, 19 May 1999.
15. Molnar, J.; Mucsi, I.; Nacs, J.; Hever, A.; Gyemánt, N.; Ugocsai, K.; Hegye, P.; Kiessig, S.T.; Gaal, D.; Lage, H.; et al. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells. *Anticancer Res.* **2004**, *24*, 865–872. [[PubMed](#)]
16. Kars, M.D.; Iseri, O.D.; Gunduz, U.; Ural, A.U.; Arpacı, F.; Molnar, J. Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds. *Anticancer Res.* **2006**, *26*, 4559–4568.
17. Molnar, J.; Ocsovszki, I.; Pusztai, R. Amyloid-beta interactions with ABC transporters and resistance modifiers. *Anticancer Res.* **2018**, *38*, 3407–3410. [[CrossRef](#)]
18. Zalatnai, A.; Molnar, J. Effect of SILA-409, a new organosilicon multidrug- resistance modifier, on human pancreatic cancer xenografts. *In Vivo* **2006**, *20*, 137–140.
19. Olszewski, U.; Zeillinger, R.; Kars, M.D.; Zalatnai, A.; Molnar, J.; Hamilton, G. Anticancer effects of the organosilicon multidrug-resistance modulator SILA 421. *Anticancer Agents Med. Chem.* **2012**, *12*, 663–671. [[CrossRef](#)]
20. Martins, M.; Viveiros, M.; Ramos, J.; Couto, I.; Molnar, J.; Boeree, M.; Amaral, L. SILA-421, an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular extensively drug-resistant tuberculosis (XDR-TB). *Int. J. Antimicrob. Ag.* **2009**, *33*, 479–482. [[CrossRef](#)]
21. Simons, S.O.; Kristiansen, J.E.; Hajos, G.; van der Laan, T.; Molnár, J.; Boeree, M.J.; van Ingen, J.; Christensen, J.B.; Viveiros, M.; Riedl, Z.; et al. Activity of the efflux pump inhibitor SILA 421 against drug-resistant tuberculosis. *Int. J. Antimicrob. Ag.* **2013**, *41*, 488–489. [[CrossRef](#)]
22. De Knecht, G.J.; Bakker-Woudenberg, I.A.; van Soolingen, D.; Aarnoutse, R.; Boeree, M.J.; de Steenwinkel, J.E. SILA-421 activity in vitro against rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis, and in vivo in a murine tuberculosis model. *Int. J. Antimicrob. Ag.* **2015**, *46*, 66–72. [[CrossRef](#)] [[PubMed](#)]
23. Schelz, Z.; Martins, M.; Martins, A.; Viveiros, M.; Molnar, J.; Amaral, L. Elimination of plasmids by SILA compounds that inhibit efflux pumps of bacteria and cancer cells. *In Vivo* **2007**, *21*, 635–639.
24. Tokuda, H.; Maoka, T.; Suzuiki, N.; Hohmann, J.; Vasas, A.; Engi, H.; Mucsi, I.; Olszewski, U.; Hamilton, G.; Amaral, L.; et al. Effects of two disiloxanes ALIS-409 and ALIS-421 on chemoprevention in model experiments. *Anticancer Res.* **2013**, *33*, 2021–2027. [[PubMed](#)]
25. Wesołowska, O.; Wiśniewski, J.; Środa, K.; Krawczyński, A.; Bielawska-Pohl, A.; Paprocka, M.; Duś, D.; Michalak, K. 8-Prenylnaringenin is an inhibitor of multidrug resistance associated transporters, P-glycoprotein and MRP1. *Eur. J. Pharmacol.* **2010**, *644*, 32–40. [[CrossRef](#)] [[PubMed](#)]
26. Dobhal, M.P.; Li, G.; Gryshuk, A.; Graham, A.; Bhatnager, A.K.; Khaja, S.D.; Joshi, Y.C.; Sharma, M.C.; Oseroff, A.; Pandey, R.K. Structural modifications of plumieride isolated from *Plumeria bicolor* and the effect of these modifications on in vitro anticancer activity. *J. Org. Chem.* **2004**, *69*, 6165–6172. [[CrossRef](#)] [[PubMed](#)]
27. Carella, A.; Roviello, V.; Iannitti, R.; Palumbo, R.; La Manna, S.; Marasco, D.; Trifuoggi, M.; Diana, R.; Roviello, G.N. Evaluating the biological properties of synthetic 4-nitrophenyl functionalized benzofuran derivatives with telomeric DNA binding and antiproliferative activities. *Int. J. Biol. Macromol.* **2019**, *121*, 77–88. [[CrossRef](#)]

28. Środa-Pomianek, K.; Michalak, K.; Świątek, P.; Poła, A.; Palko-Łabuz, A.; Wesołowska, O. Increased lipid peroxidation, apoptosis and selective cytotoxicity in colon cancer cell line LoVo and its doxorubicin-resistant subline LoVo/Dx in the presence of newly synthesized phenothiazine derivatives. *Biomed. Pharmacother.* **2018**, *106*, 624–636. [[CrossRef](#)]
29. Deo, K.M.; Sakoff, J.; Gilbert, J.; Zhang, Y.; Aldrich Wright, J.R. Synthesis, characterisation and influence of lipophilicity on cellular accumulation and cytotoxicity of unconventional platinum(IV) prodrugs as potent anticancer agents. *Dalton Trans.* **2019**, *48*, 17228–17240. [[CrossRef](#)]
30. Środa-Pomianek, K.; Michalak, K.; Palko-Łabuz, A.; Poła, A.; Dziegiel, P.; Puła, B.; Świątek, P.; Wesołowska, O. Cytotoxic and multidrug resistance reversal activity of phenothiazine derivative is strongly enhanced by theobromine, a phytochemical from cocoa. *Eur. J. Pharmacol.* **2019**, *849*, 124–134. [[CrossRef](#)]
31. Grandi, M.; Geroni, C.; Giuliani, F.C. Isolation and characterization of a human colon adenocarcinoma cell line resistant to doxorubicin. *Br. J. Cancer* **1986**, *54*, 515–518. [[CrossRef](#)]
32. Pastan, I.; Gottesman, M.M.; Ueda, K.; Lovelace, E.; Rutherford, A.V.; Willingham, M.C. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. *Proc. Natl. Acad. Sci. USA* **1988**, *85*, 4486–4490. [[CrossRef](#)] [[PubMed](#)]
33. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J.T.; Bokesch, H.; Kenney, S.; Boyd, M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. *J. Natl. Cancer Inst.* **1990**, *82*, 1107–1112. [[CrossRef](#)] [[PubMed](#)]
34. Palko-Łabuz, A.; Środa-Pomianek, K.; Uryga, A.; Kostrzewa-Susłow, E.; Michalak, K. Anticancer activity of baicalein and luteolin studied in colorectal adenocarcinoma LoVo cells and in drug-resistant LoVo/Dx cells. *Biomed. Pharmacother.* **2017**, *88*, 232–241. [[CrossRef](#)]
35. Chou, T.C.; Martin, N. *CompuSyn for Drug Combinations: PC Software and User's Guide: A Computer Program for Quantitation of Synergism and Antagonism in Drug Combinations, and the Determination of IC50 and ED50 and LD50 Values*; ComboSyn Inc.: Paramus, NJ, USA, 2005.
36. Riganti, C.; Miraglia, E.; Viarisio, D.; Costamagna, C.; Pescarmona, G. Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. *Cancer Res.* **2005**, *65*, 516–525.
37. Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem.* **1976**, *72*, 248–254. [[CrossRef](#)]

Sample Availability: Samples of the compounds are not available from the authors.



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).